相关实验视频

Updated: May 24, 2025

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

多糖类作为胰腺癌的治疗载体

Seema Kumari¹, Sujatha Peela¹, Ganji Purnachandra Nagaraju²

¹Department of Biotechnology, Dr. B.R. Ambedkar University, Srikakulam 532410 AP, India.

Drug discovery today

|March 2, 2025

概括

基于多糖的疗法显示,通过向瘤微环境 (TME) 和克服药物耐药性,对胰腺癌 (PC) 治疗有希望. 这些先进的药物输送系统提高了激进PC的化疗疗效率.

科学领域:

在瘤学瘤学.
生物医学工程生物医学工程
药物运输药物运输药物运输

背景情况:

胰腺癌 (PC) 是一种高度侵略性的恶性瘤,发病率和死亡率不断增加.
显著的治疗挑战包括晚检测,密集的瘤微环境 (TME) 和治疗耐药性.
目前PC的治疗选择有限,需要新的治疗策略.

研究的目的:

探索基于多糖的疗法在克服PC治疗障碍方面的潜力.
调查如何针对TME可以改善胰腺癌的治疗结果.
评估先进的药物输送系统,以提高PC的化疗疗效率.

主要方法:

对针对瘤微环境 (TME) 进行胰腺癌 (PC) 治疗的近期进展的审查.
分析利用多糖体 (例如,小粒体,脂质体,纳米粒子) 的新型聚合物药物递送系统.
对RP02-1和DPLL功能化粉素等特定多糖基剂的临床前数据的检查.

主要成果:

基于多糖的药物输送系统增强了药物的溶解性,稳定性和瘤特异性向.
这些系统显示出绕过胰腺癌治疗耐药性的潜力.
临床前研究表明,用RP02-1和DPLL功能化粉素等药物调节TME可以提高化疗疗效.

结论:

基于多糖的疗法是改善胰腺癌治疗结果的有希望的途径.
针对TME和利用先进的药物输送是克服PC耐药性的关键策略.
对RP02-1和DPLL功能化粉素等药物的进一步研究可能会导致更有效的PC疗法.

关键词:

送货送货送货送货送货送货免疫调节免疫调节免疫调节胰腺癌是一种癌症.聚合物是一种聚合物.聚糖类是一种多糖类.

更多相关视频

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

相关概念视频

Insulin: Biosynthesis, Chemistry, and Preparation

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...